Halozyme Therapeutics, Inc. (HALO)
110.19
-0.57
(-0.51%)
USD |
NASDAQ |
Sep 04, 16:00
109.96
-0.23
(-0.21%)
After-Hours: 20:00
Halozyme Therapeutics Research and Development Expense (Quarterly) : 27.66M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.66M |
| March 31, 2026 | 25.56M |
| December 31, 2025 | 31.90M |
| September 30, 2025 | 17.25M |
| June 30, 2025 | 17.54M |
| March 31, 2025 | 14.80M |
| December 31, 2024 | 20.44M |
| September 30, 2024 | 18.46M |
| June 30, 2024 | 21.04M |
| March 31, 2024 | 19.11M |
| December 31, 2023 | 21.34M |
| September 30, 2023 | 17.32M |
| June 30, 2023 | 19.73M |
| March 31, 2023 | 17.98M |
| December 31, 2022 | 22.57M |
| September 30, 2022 | 16.70M |
| June 30, 2022 | 15.48M |
| March 31, 2022 | 11.85M |
| December 31, 2021 | 10.11M |
| September 30, 2021 | 8.486M |
| June 30, 2021 | 8.069M |
| March 31, 2021 | 9.009M |
| December 31, 2020 | 7.38M |
| September 30, 2020 | 7.747M |
| June 30, 2020 | 8.951M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.16M |
| December 31, 2019 | 27.91M |
| September 30, 2019 | 30.46M |
| June 30, 2019 | 32.91M |
| March 31, 2019 | 31.33M |
| December 31, 2018 | 36.65M |
| September 30, 2018 | 35.54M |
| June 30, 2018 | 40.09M |
| March 31, 2018 | 37.98M |
| December 31, 2017 | 41.38M |
| September 30, 2017 | 33.99M |
| June 30, 2017 | 38.34M |
| March 31, 2017 | 36.94M |
| December 31, 2016 | 41.35M |
| September 30, 2016 | 33.86M |
| June 30, 2016 | 35.53M |
| March 31, 2016 | 40.10M |
| December 31, 2015 | 27.75M |
| September 30, 2015 | 27.61M |
| June 30, 2015 | 21.20M |
| March 31, 2015 | 16.68M |
| December 31, 2014 | 19.73M |
| September 30, 2014 | 19.90M |
| June 30, 2014 | 18.65M |
| March 31, 2014 | 21.42M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Incyte Corp. | 497.47M |
| AVITA Medical, Inc. | 5.078M |
| BioCryst Pharmaceuticals, Inc. | 51.46M |
| Neurocrine Biosciences, Inc. | 326.70M |
| Iovance Biotherapeutics, Inc. | 58.85M |